Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -2.61M | -2.52M | -2.57M | -2.70M | -2.26M |
| Total Depreciation and Amortization | 10.00K | 10.00K | 10.00K | 9.00K | 9.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 635.00K | 669.00K | 823.00K | 834.00K | 820.00K |
| Change in Net Operating Assets | 191.00K | 96.00K | -878.00K | 597.00K | -82.00K |
| Cash from Operations | -1.77M | -1.74M | -2.61M | -1.26M | -1.51M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -245.00K | 422.00K | 1.23M | 654.00K | -833.00K |
| Cash from Investing | -245.00K | 422.00K | 1.23M | 654.00K | -833.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.14M | 2.87M | 60.00K | 332.00K | 2.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -207.00K | -1.63M | 1.63M | 18.00K | -123.00K |
| Cash from Financing | 1.94M | 1.25M | 1.69M | 350.00K | 1.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -79.00K | -70.00K | 303.00K | -251.00K | -415.00K |